{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:55:27Z","timestamp":1788580527747,"version":"build-2803163510"},"reference-count":44,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Throughout the last decades, newly developed chemotherapeutic agents and immunotherapies that target signaling pathways have provided patients with better prognoses, improved their quality of life and increased survival rates, thus converting cancer to a stable chronic disease. However, non-anthracycline cancer chemotherapy agents and immunotherapies including human epidermal growth factor receptor 2 (HER2) inhibitors, vascular endothelial growth factor (VEGF) inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), proteasome inhibitors, immune checkpoint inhibitors and chimeric antigen receptor T cells (CAR-T cells) may cause cardiovascular toxicity events and complications that usually interrupt the continuation of an appropriate treatment regimen, which induces life-threatening risks or leads to long-term morbidity. Heart failure, cardiac arrythmias and cardiomyopathies are the most common cardiovascular events related to cardiotoxicity due to chemotherapy. Each patient should be carefully assessed and monitored before, during and after the administration of chemotherapy, to address any predisposing risk factors and the new onset of cardiotoxicity manifestations early and treat them appropriately. The development of novel anticancer agents that cause minimal cardiovascular toxicity events or novel agents that ameliorate the adverse effects of the existing anticancer agents could drastically change the field of cardio-oncology. The aim of this narrative review is to demonstrate new knowledge regarding the screening and diagnosis of non-anthracycline-induced cardiotoxicity and to propose protective measures that could be performed in order to achieve the delivery of optimal care.<\/jats:p>","DOI":"10.3390\/jcdd9030066","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T22:54:02Z","timestamp":1645656842000},"page":"66","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5740-9670","authenticated-orcid":false,"given":"Alexandros","family":"Briasoulis","sequence":"first","affiliation":[{"name":"Department of Clinical Therapeutics, National Kapodistrian University of Athens, 11528 Athens, Greece"},{"name":"Division of Cardiovascular Diseases, University of Iowa Hospitals and Clinics, Iowa City, IA 52245, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeliki","family":"Chasouraki","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, National Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Sianis","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, National Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Panagiotou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, National Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4348-2153","authenticated-orcid":false,"given":"Christos","family":"Kourek","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, National Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argyrios","family":"Ntalianis","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, National Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Paraskevaidis","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, National Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3322\/caac.21149","article-title":"Cancer treatment and survivorship statistics","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/CIRCRESAHA.109.205906","article-title":"The vulnerability of the heart as a pluricellular paracrine organ: Lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy","volume":"106","author":"Doggen","year":"2010","journal-title":"Circ. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e018403","DOI":"10.1161\/JAHA.120.018403","article-title":"Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines","volume":"9","author":"Alexandre","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-019-05303-y","article-title":"HER2+ breast cancer treatment and cardiotoxicity: Monitoring and management","volume":"177","author":"Jerusalem","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1111\/bph.13643","article-title":"Trastuzumab cardiotoxicity: From clinical trials to experimental studies","volume":"174","author":"Nemeth","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1074\/jbc.M804570200","article-title":"Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways","volume":"284","author":"Gordon","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_9","first-page":"CD006242","article-title":"Trastuzumab-containing regimens for metastatic breast cancer","volume":"2014","author":"Balduzzi","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_10","first-page":"1132","article-title":"Cardiotoxicity of chemotherapy and targeted agents","volume":"11","author":"Mudd","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e002843","DOI":"10.1161\/CIRCHEARTFAILURE.115.002843","article-title":"Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions","volume":"9","author":"Hamo","year":"2016","journal-title":"Circ. Heart Fail."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1161\/HYPERTENSIONAHA.117.08856","article-title":"Recent Advances in Hypertension and Cardiovascular Toxicities with Vascular Endothelial Growth Factor Inhibition","volume":"70","author":"Touyz","year":"2017","journal-title":"Hypertension"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41698-018-0056-z","article-title":"Cardiotoxicity with vascular endothelial growth factor inhibitor therapy","volume":"2","author":"Touyz","year":"2018","journal-title":"NPJ Precis. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e002661","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","article-title":"Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging","volume":"9","author":"Bloom","year":"2016","journal-title":"Circ. Heart Fail."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.critrevonc.2014.12.008","article-title":"Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"94","author":"Ghatalia","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.jacc.2017.09.1095","article-title":"Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2","volume":"70","author":"Chang","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11912-020-00931-w","article-title":"Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management","volume":"22","author":"Wu","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","article-title":"Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1","volume":"70","author":"Chang","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaccao.2020.11.012","article-title":"The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer","volume":"3","author":"Zhang","year":"2021","journal-title":"JACC CardioOncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"S\u0142awi\u0144ski, G., Wrona, A., D\u0105browska-Kugacka, A., Raczak, G., and Lewicka, E. (2020). Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197195"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11936-020-00867-1","article-title":"Cardiotoxicity of Contemporary Anticancer Immunotherapy","volume":"22","author":"Patel","year":"2020","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11886-021-01440-3","article-title":"Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies","volume":"23","author":"Rothberg","year":"2021","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"23","author":"Ganatra","year":"2018","journal-title":"Oncologist"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in Patients Treated with Immune Checkpoint Inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant Myocarditis with Combination Immune Checkpoint Blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11912-021-01070-6","article-title":"Cardiotoxicity of Immune Checkpoint Inhibitors","volume":"23","author":"Patel","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","article-title":"Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations","volume":"72","author":"Ferreira","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis","volume":"41","author":"Zhang","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","article-title":"Cardiovascular Effects of CAR T Cell Therapy: A Retrospective Study","volume":"2","author":"Lefebvre","year":"2020","journal-title":"JACC CardioOncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","article-title":"Chimeric Antigen Receptor T-Cell Therapy-Associated Cardiomyopathy in Patients with Refractory or Relapsed Non-Hodgkin Lymphoma","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients with Breast Cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: The OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)","volume":"61","author":"Bosch","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaccao.2019.08.006","article-title":"Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients with Cancer Undergoing Chemotherapy","volume":"1","author":"Vaduganathan","year":"2019","journal-title":"JACC CardioOncol."},{"key":"ref_43","first-page":"ehab843","article-title":"Mansson-Broberg, A. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer","volume":"24","author":"Lewinter","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1001\/jamaoncol.2021.3395","article-title":"Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial","volume":"7","author":"Livi","year":"2021","journal-title":"JAMA Oncol."}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/9\/3\/66\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:25:43Z","timestamp":1760135143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/9\/3\/66"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["jcdd9030066"],"URL":"https:\/\/doi.org\/10.3390\/jcdd9030066","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,23]]}}}